Fulcrum Therapeutics (FULC) Equity Ratio: 2019-2025
Historic Equity Ratio for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to 0.92.
- Fulcrum Therapeutics' Equity Ratio rose 0.12% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 0.12%. This contributed to the annual value of 0.93 for FY2024, which is 2.14% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Equity Ratio stood at 0.92 for Q3 2025, which was down 1.45% from 0.94 recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Equity Ratio ranged from a high of 0.94 in Q1 2025 and a low of 0.80 during Q2 2021.
- Moreover, its 3-year median value for Equity Ratio was 0.92 (2023), whereas its average is 0.92.
- Examining YoY changes over the last 5 years, Fulcrum Therapeutics' Equity Ratio showed a top increase of 22.55% in 2021 and a maximum decrease of 4.61% in 2021.
- Fulcrum Therapeutics' Equity Ratio (Quarterly) stood at 0.90 in 2021, then decreased by 2.51% to 0.88 in 2022, then rose by 4.00% to 0.91 in 2023, then grew by 2.14% to 0.93 in 2024, then grew by 0.12% to 0.92 in 2025.
- Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.94 for Q2 2025 and 0.94 for Q1 2025.